24 Aug 2022 ADOCIA Reports Cash and Revenue for the Second Quarter and Provides Corporate Update Icon check
11 Jul 2022 Number of shares and voting rights of ADOCIA as of June 30th, 2022 Icon check
23 Jun 2022 Adocia publishes its Letter to Shareholders Icon check
23 Jun 2022 ADOCIA – Letter to Shareholders – June 2022 Icon check
21 Jun 2022 ADOCIA announces M1Pram Phase 2 Trial Meets Primary Objective by Reducing Weight in Overweight People with Type 1 Diabetes Icon check
14 Jun 2022 Number of shares and voting rights of ADOCIA as of May 31st, 2022 Icon check
20 May 2022 ADOCIA Announces its annual Shareholders’ meeting to be held on June 28, 2022 in Paris Icon check
18 May 2022 ADOCIA Reports Financial Results of First Quarter 2022 and Provides Corporate Update Icon check
18 May 2022 ADOCIA Announces The First Subject Treated In BioChaperone® Combo Clinical Studies with Partner Tonghua Dongbao Icon check
13 May 2022 Number of shares and voting rights of ADOCIA as of April 30th, 2022 Icon check
09 May 2022 ADOCIA Announces the First Patient Dosed In the BioChaperone® Lispro Phase 3 Program with Partner Tonghua Dongbao Icon check
25 Apr 2022 ADOCIA Announces the Release of its Universal Registration Document for the Year 2021 Icon check
19 Apr 2022 ADOCIA announces its annual results for 2021 and presents an update on activities Icon check
15 Apr 2022 Number of shares and voting rights of ADOCIA as of March 31st, 2022 Icon check
11 Apr 2022 ADOCIA Announces Start of 3 Clinical Studies for BioChaperone® Combo with Partner Tonghua Dongbao Icon check
28 Mar 2022 Adocia strengthens its cash position by 19 million euros following a real estate transaction Icon check
16 Mar 2022 Number of shares and voting rights of ADOCIA as of February 28th, 2022 Icon check
23 Feb 2022 ADOCIA announces 2021 fourth quarter financial results Icon check
15 Feb 2022 Number of shares and voting rights of ADOCIA as of January 31st, 2021 Icon check
11 Jan 2022 Number of shares and voting rights of ADOCIA as of December 31st, 2021 Icon check
06 Jan 2022 ADOCIA announces its financial calendar for 2022 Icon check
20 Dec 2021 ADOCIA Announces its Participation at Upcoming Investor Conferences in January 2022 Icon check
15 Dec 2021 Number of shares and voting rights of ADOCIA as of November 30th, 2021 Icon check
13 Dec 2021 Adocia Files Patent for Technology to Enable Oral Drug Delivery of Peptides Icon check
19 Nov 2021 Number of shares and voting rights of ADOCIA as of October 31st, 2021 Icon check
26 Oct 2021 Adocia announces 2021 third quarter financial results and a financing of €7 million Icon check
14 Oct 2021 ADOCIA’s partner Tonghua Dongbao Receives Clearance to Start Ultra-Rapid Insulin BioChaperone® Lispro Phase 3 Trial in China Icon check
12 Oct 2021 Number of shares and voting rights of ADOCIA as of September 30th, 2021 Icon check
21 Sep 2021 ADOCIA announces Oral Presentation Reviewing M1Pram (ADO09) at the occasion of the 57th Annual Meeting of EASD Icon check
13 Sep 2021 Number of shares and voting rights of ADOCIA as of August 31st, 2021 Icon check
10 Sep 2021 Adocia To Participate in the H.C. Wainwright 23rd Annual Global Investment Conference Icon check
07 Sep 2021 ADOCIA Announces First Half 2021 Financial Results and Provides an Update on Activities Icon check
23 Aug 2021 Number of shares and voting rights of ADOCIA as of July 31st, 2021 Icon check
29 Jul 2021 Bilan Semestriel du contrat de liquidité Adocia conclu avec la société Kepler Capital Markets
22 Jul 2021 ADOCIA Announces Second Quarter 2021 Financial Results Icon check
15 Jul 2021 Number of shares and voting rights of ADOCIA as of June 30th, 2021 Icon check
29 Jun 2021 ADOCIA Initiates BC LisPram Phase 1 Clinical Trial in Pump for People with Type 1 Diabetes Icon check
27 Jun 2021 ADO09, a coformulation of insulin A21G and pramlintide (Pram), improves blood glucose control and reduces body weight in subjects with T1D, Dr. Grégory Meiffren, June 27, 2021, ADA virtual event.
15 Jun 2021 ADOCIA Announces M1Pram Clinical Data Presentation at the American Diabetes Association® 81st Scientific Sessions Icon check
10 Jun 2021 Number of shares and voting rights of ADOCIA as of May 31st, 2021 Icon check
08 Jun 2021 ADOCIA confirms its eligibility for the PEA–PME Icon check
02 Jun 2021 ADO09, a co-formulation of pramlintide and insulin A21G improves postprandial glucose (PPG) versus insulin Aspart  in type 1 diabetes, Dr.  Grégory Meiffren, June 2, 2021, ATTD, Virtual event.
02 Jun 2021 ADOCIA Presents Clinical Results on M1Pram at the 14th International Conference on ATTD 2021 Icon check
01 Jun 2021 ADOCIA reinforces its board of directors with the appointment of three new independent members. Icon check
26 May 2021 ADOCIA Expands Clinical Development to Obesity with Patent Applications on Short-Acting Multihormonal Combinations Administered by Pumps Icon check
17 May 2021 Number of shares and voting rights of ADOCIA as of April 30, 2021 Icon check
11 May 2021 ADOCIA Announces the Live Broadcast of its Annual General Meeting on May 20th, 2021 Icon check
23 Apr 2021 ADO09, a co‐formulation of the amylin analogue pramlintide and the insulin analogue A21G, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes. Diabetes Obes Metab., 2021;23(4):961-970. Icon check
21 Apr 2021 ADOCIA Announces the Release of its Universal Registration Document for the Year 2020 Icon check
21 Apr 2021 ADOCIA Announces First Quarter 2021 Financial Results Icon check
Join our mailing list. Subscribe